Modelling Spillover Effects on Informal Carers: The Carer QALY Trap-Reference-Cited by-同舟云学术

Modelling Spillover Effects on Informal Carers: The Carer QALY Trap

Published:2023-09-02 Issue:12 Volume:41 Page:1557-1561
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Mott David J.^ORCID,Schirrmacher Hannah^ORCID,Al-Janabi Hareth^ORCID,Guest Sophie,Pennington Becky^ORCID,Scheuer Nicolas,Shah Koonal K.^ORCID,Skedgel Chris^ORCID

Funder

Roche Products

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01316-0.pdf

Reference21 articles.

1. Leech AA, Lin P-J, D’Cruz B, Parsons SK, Lavelle TA. Family spillover effects: are economic evaluations misrepresenting the value of healthcare interventions to society? Appl Health Econ Health Policy. 2023;21:5–10. https://doi.org/10.1007/s40258-022-00755-8.

2. Canaway A, Al-Janabi H, Kinghorn P, Bailey C, Coast J. Close-person spill-overs in end-of-life care: using hierarchical mapping to identify whose outcomes to include in economic evaluations. Pharmacoeconomics. 2019;37:573–83. https://doi.org/10.1007/s40273-019-00786-5.

3. Wu Y, Al-Janabi H, Mallett A, Quinlan C, Scheffer IE, Howell KB, Christodoulou J, Leventer RJ, Lockhart PJ, Stark Z, Boughtwood T, Goranitis I. Parental health spillover effects of paediatric rare genetic conditions. Qual Life Res. 2020;29:2445–54. https://doi.org/10.1007/s11136-020-02497-3.

4. Al-Janabi H, van Exel J, Brouwer W, Coast J. A framework for including family health spillovers in economic evaluation. Med Decis Mak. 2016;36:176–86. https://doi.org/10.1177/0272989X15605094.

5. Brouwer WBF. The inclusion of spillover effects in economic evaluations: not an optional extra. Pharmacoeconomics. 2019;37:451–6. https://doi.org/10.1007/s40273-018-0730-6.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Methods and Practice for Integrating Maternal, Fetal, and Child Health Outcomes, and Family Spillover Effects into Cost-Utility Analyses;PharmacoEconomics;2024-05-31

2. Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?;PharmacoEconomics;2024-05-11

3. Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap;PharmacoEconomics;2024-03-05

4. The Carer QALY Trap and Altruism in Economic Evaluations;PharmacoEconomics;2023-11-02